Optibrium and Lhasa entered into a technology collaboration agreement that will integrate Lhasa’s Derek Nexus™ platform for knowledge-based prediction of compound toxicity as an optional plug-in module for Optibrium’s StarDrop software.
Sigma Life Science’s Sigma Advanced Genetic Engineering (SAGE) Labs, and Ekam Imaging are teaming up to develop a suite of preclinical services that will combine SAGE’s rat models of neurological disorders and Ekam’s functional magnetic resonance imaging (fMRI) technology.
Funds will be used to continue clinical development of lead LAL deficiency enzyme replacement therapy.
Firm will seek approval of a range of diagnostic assays for the platform.
Glycan-binding anti-inflammatory protein designed to block activation of neutrophils.
Listeria-based platform will be leveraged against tularemia, HBV, and melanoma.
Firm aims to push on with Phase IIb trial of quinolone candidate delafloxacin.
Tesaro picked up the rights to antibody drug candidates from AnaptysBio targeting TIM-3, LAG-3 and PD-1 and dual-reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3.